Kimberly Martin - Alcon AG VP Officer

ALC Stock  USD 85.57  0.07  0.08%   

Insider

Kimberly Martin is VP Officer of Alcon AG
Age 49
Address Chemin de Blandonnet 8, Geneva, Switzerland, 1214
Phone41 589 112 110
Webhttps://www.alcon.com

Alcon AG Management Efficiency

The company has Return on Asset of 0.0255 % which means that on every $100 spent on assets, it made $0.0255 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0559 %, implying that it generated $0.0559 on every 100 dollars invested. Alcon AG's management efficiency ratios could be used to measure how well Alcon AG manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to 0.09. The current year's Return On Capital Employed is expected to grow to 0.04. At present, Alcon AG's Other Assets are projected to decrease significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 1.5 B, whereas Total Assets are forecasted to decline to about 24.5 B.
Alcon AG has 5.13 B in debt with debt to equity (D/E) ratio of 0.22, which may show that the company is not taking advantage of profits from borrowing. Alcon AG has a current ratio of 2.12, demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due. Note however, debt could still be an excellent tool for Alcon to invest in growth at high rates of return.

Similar Executives

Showing other executives

INSIDER Age

Brian BonnellICU Medical
50
Justin LeongResMed Inc
47
James WintersTeleflex Incorporated
48
Jacqueline KunzlerBaxter International
55
Nicole PriestMerit Medical Systems
N/A
Daniel RaskasEnvista Holdings Corp
54
Mischa ReisEnvista Holdings Corp
52
JeanClaude KyrillosEnvista Holdings Corp
60
Amy WakehamResMed Inc
N/A
Ajay KumarEmbecta Corp
53
Molly JosephWest Pharmaceutical Services
46
Josep LlorensHaemonetics
62
Kimberly MacKayWest Pharmaceutical Services
58
Warner HThe Cooper Companies,
56
Lloyd JohnsonHaemonetics
66
BE MBAResMed Inc
50
Michel VoigtMerit Medical Systems
51
Daniel LogueTeleflex Incorporated
50
Amy McbrideWendellBaxter International
60
Neil PetersonMerit Medical Systems
57
CPA ParraMerit Medical Systems
46
Alcon Inc., an eye care company, researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland. Alcon operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 24000 people. Alcon AG (ALC) is traded on New York Stock Exchange in USA. It is located in Chemin de Blandonnet 8, Geneva, Switzerland, 1214 and employs 25,000 people. Alcon AG is listed under Health Care Equipment & Supplies category by Fama And French industry classification.

Management Performance

Alcon AG Leadership Team

Elected by the shareholders, the Alcon AG's board of directors comprises two types of representatives: Alcon AG inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Alcon. The board's role is to monitor Alcon AG's management team and ensure that shareholders' interests are well served. Alcon AG's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Alcon AG's outside directors are responsible for providing unbiased perspectives on the board's policies.
Dieter Spaelti, Independent Director
Arthur MD, Executive Director
Ian Bell, President - Global Business and Innovation
Royce Bedward, General VP
Michael Onuscheck, President - Global Businesses and Innovation
Ed McGough, Senior Operations
Sergio Duplan, President - North America
Karen May, Independent Director
Timothy Stonesifer, Chief Financial Officer
Michael Ball, Executive Chairman
Scott Maw, Independent Director
Ines Poeschel, Independent Director
Margaret Buckley, Chief Officer
Leon Fraustro, President - North America
Thomas Glanzmann, Independent Director
Arthur Cummings, Independent Director
S Attias, Head Corporate Development, Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)
F Ball, Chairman of the Board ( Designate )
D Grossman, Independent Vice Chairman of the Board, Lead Independent Director
Lynn Bleil, Independent Director
Dieter Spalti, Independent Director
Franck Leveiller, Head VP
David Endicott, Chief Executive Officer, Director
Kimberly Martin, VP Officer
Royce JD, General VP
Rajkumar Narayanan, Senior Vice President - Operational Strategy, Chief Transformation Officer
Ines Poschel, Independent Director
SueJean Lin, Senior Vice President, Chief Information and Transformation Officer
Laurent Attias, Head Corporate Development, Strategy, Business Development and Licensing (BD&L) and Mergers and Acquisitions (M&A)

Alcon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Alcon AG a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Alcon AG offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alcon AG's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alcon Ag Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alcon Ag Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alcon AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For information on how to trade Alcon Stock refer to our How to Trade Alcon Stock guide.
You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alcon AG. If investors know Alcon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alcon AG listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.293
Earnings Share
2.34
Revenue Per Share
19.757
Quarterly Revenue Growth
0.054
Return On Assets
0.0255
The market value of Alcon AG is measured differently than its book value, which is the value of Alcon that is recorded on the company's balance sheet. Investors also form their own opinion of Alcon AG's value that differs from its market value or its book value, called intrinsic value, which is Alcon AG's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alcon AG's market value can be influenced by many factors that don't directly affect Alcon AG's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alcon AG's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alcon AG is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alcon AG's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.